MedTrace Logo

KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors

NCT02250885 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2019-09-17

No results posted yet for this study

Summary

Evaluate the efficacy of Selinexor in patients with poorly differentiated lung and gastrointestinal and pancreatic neuroendocrine tumors.

Conditions

  • Carcinoma, Neuroendocrine

Interventions

DRUG

Selinexor

Selective Inhibitor fo Nuclear Export (SINE)

Sponsors & Collaborators

  • Karyopharm Therapeutics Inc

    collaborator INDUSTRY

  • Gabrail Cancer Center Research

    lead OTHER

Principal Investigators

  • Nashat Y Gabrail, MD · Gabrail Cancer Center Research

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-31
Primary Completion
2016-08-31
Completion
2016-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02250885 on ClinicalTrials.gov